INDONESIA CLAIMS A POSSESSION OF 1.2 MILLION COVID-19 VACCINE
A 1.2 million doses of COVID-19 vaccine Indonesia received from China’s Sinovac Biotech on Dec 6 and is set to receive raw materials to produce 15 million doses from the same company later this month.
The arrival of the first batch of CoronaVac is part of a deal between Indonesia and Sinovac as the country has been testing the vaccine in a late-stage clinical trial since August.
There will be another 1.8 million doses of the jabs are expected to be sent to Indonesia by January the latest, followed by raw materials to produce 30 million doses of the vaccine in the same month.
The deal guaranteed Indonesia priority access to the technical know-how on producing the vaccine, so that its state-owned pharmaceutical firm Bio Farma can produce the jabs with the raw materials.
Bio Farma is the country’s only vaccine producer and has been partnering with the University of Padjajaran to conduct the trials in Southeast Asia’s biggest country.
Late-stage trials of the Sinovac vaccine are also being carried out in Brazil, Chile and Turkey.
Bio Farma’s head of clinical trials Rini Mulia Sari had said back in August during a media briefing at the company’s headquarter in Bandung city,
“There will also be a transfer of technology. So, the ones that will be marketed (in Indonesia) will be those manufactured at Bio Farma, meaning it will carry Bio Farma’s brand.”
From their tally, 1,620 volunteers have taken part in the clinical trial since August which is scheduled to last over a period of six months.
The latest development comes as Indonesia prepares for a mass vaccination to stop the spread of COVID-19 in the archipelago which has so far infected more than 600,000 people and caused more than 19,000 deaths.